Epigral Ltd (EPIGRAL) Q1FY26 Concall Summary - Jun-2025 Qtr
Performance Overview
- Epigral Ltd. experienced a 6% revenue degrowth in Q1 FY26, primarily due to planned maintenance work at the plant and early monsoon season.
- Despite the revenue decline, EBITDA margin remained stable at 27% due to operational efficiency and a favorable product mix.
- Derivatives and specialty business contributed 50% to revenue, with expectations of reaching 70% in coming years, driven by ongoing CapEx projects.
- CapEx projects, including capacity doubling of CPVC and an epic chloride plant, along with a 19.80 MW wind-solar hybrid power plant, are progressing as scheduled.
- The company is evaluating a new project at the existing site to further strengthen the integrated complex and exploring new chemistry for growth beyond 2028.
Financial Metrics
Log in to Stocksigma to read the Financial Metrics section of this summary.
Operating Performance / Business Segments
Log in to Stocksigma to read the Operating Performance / Business Segments section of this summary.
Key Discussions & Insights
Log in to Stocksigma to read the Key Discussions & Insights section of this summary.
Outlook and Guidance
Log in to Stocksigma to read the Outlook and Guidance section of this summary.
Challenges / Concerns
Log in to Stocksigma to read the Challenges / Concerns section of this summary.
Industry / Competitive Landscape
Log in to Stocksigma to read the Industry / Competitive Landscape section of this summary.
Overall Summary
Log in to Stocksigma to read the Overall Summary section of this summary.